CClinicalTrials.gg
CompletedNCT03639337Updated Aug 28, 2018

Colonization and Persistence Capacity of a Multi-strain Probiotics in Pediatric Food Allergy to Milk or Egg.

An interventional study of Multi-strain probiotic in Food Hypersensitivity and Probiotic, sponsored by Bambino Gesù Hospital and Research Institute. Completed at 1 site in Italy. Open to participants aged 10 Months to 14 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-28.

Sponsored by Bambino Gesù Hospital and Research Institute · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
10 Months to 14 Months
Sex
All
01

Study summary

This study evaluates the addition of three probiotics (Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium infantis) in the treatment of pediatric food allergic children to milk or egg. The allergic participants will receive the probiotics, while other two populations age and sex matched of not confirmed allergic and healthy children will not receive probiotics.

Read the detailed description

This study evaluates the colonization capacity of three probiotics (Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium infantis) in milk and/or egg allergic children.

It is expected the recruitment of about 20 egg and/or milk allergic patients aged between 10 and 14 months old confirmed with double-blind oral tolerance test against placebo (Group 1).

Furthermore, about 10 patients sensible to milk or egg but not confirmed with double-blind oral tolerance test against placebo (Group 2) will be recruited and about 10 healthy individuals (Group 3).

For all 40 patients:

  1. Baseline presence of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63 will be evaluated;

    Only for Group 1 children it will be also evaluate:

  2. The presence of the same strains during 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63 and after 60 days from the suspension of the administration.

Quantification of B. breve, B. longum subsp. longum and B. longum subsp. infantis in faecal samples was carried out by qRT-PCR using the Light Cycler 480 platform (Roche Diagnostics, Mannheim, Germany). The assays were performed with a 20 µl PCR amplification mixture containing: 10 µl LightCycler 480 Probe Master mix (Roche Diagnostics), 2 µl primers and probes (optimized concentrations, 0.5 µM and 0.1 µM, respectively), 3 µl molecular-grade H2O and 5 µl DNA template. Each sample was tested in duplicate to ensure data reproducibility. The RT-PCR temperature profile consisted of an initial denaturation at 95°C for 10 min, 45 amplification cycles at 95°C for 10 sec, 60°C for 30 sec and 72°C for 1 sec followed by a final cooling step at 40°C for 30 sec. Absolute quantification was performed using the "second derivative maximum method"

Statistical analyses: Wilcoxon signed-rank test was used to compare probiotic species concentrations during the time-course.

02

Conditions studied

  • Food Hypersensitivity
  • Probiotic

Keywords

  • Probiotic
  • Food allergy
03

In context

Hypersensitivity

1,916 studies on the registry are indexed under Hypersensitivity; 265 are open to participants now.

This study's enrollment of 33 is below the median of 57 across 1,384 interventional studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

Bambino Gesù Hospital and Research Institute is the lead sponsor of 53 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Months to 14 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age between 10 and 14 months

Exclusion criteria

Exclusion Criteria:

  • gastrointestinal disease in progress or appearance in the last 30 days
  • metabolic diseases
  • antibiotic treatment in the 2 weeks prior to the start of the study;
  • intake of probiotic, fermented milk or other functional foods in the two weeks preceding the start of the study.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Allergic Children

    Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo. Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63

    Dietary Supplement: Multi-strain probiotic

  • No intervention
    Not confirmed Allergic Children

    Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.

  • No intervention
    Controls

    Healthy controls ages between 10 and 14 months

Interventions

  • Dietary supplementMulti-strain probiotic

    30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63

06

What researchers measure

Primary outcomes

  1. Basal stool concentration of Bifidobacterium longum BB536, Bifidobacterium breve M-16V

    It will be indicated number of cells per ul of stool.

    Time frame: 2 years

Secondary outcomes

  1. Stool concentration of Bifidobacterium longum BB536, Bifidobacterium breve M-16V after multi-strain probiotic administration.

    It will be indicated number of cells per ul of stool.

    Time frame: 2 years

07

Study locations

1 site
  • Ospedale Pediatrico Bambino Gesù
    Roma, Italy
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03639337
Lead sponsor
Bambino Gesù Hospital and Research Institute
Responsible party
Alessandro Giovanni Fiocchi (Director Clinical Research, Bambino Gesù Hospital and Research Institute) — Principal investigator
First posted
Aug 21, 2018
Start date
Jan 2015
Primary completion
Aug 2018
Completion
Aug 2018
Last update
Aug 28, 2018

Study contacts

Alessandro Fiocchi, M.D.
principal investigator · agiovanni.fiocchi@opbg.net

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion